A Phase 1b Dose-Escalation Study of MEK162 in Combination with Weekly Paclitaxel in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2016
At a glance
- Drugs Binimetinib (Primary) ; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Biomarker
- Sponsors Array BioPharma
- 11 Feb 2016 Planned primary completion date changed from 1 Jun 2014 to 1 Feb 2016 as per ClinicalTrials.gov record.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Primary endpoint has been met. (Establish the recommended Phase 2 dose of study drug)